- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04321551
Hormone Secretion in Transgender Males
Clinical Trial of Androgen Effects on the Reproductive Neuroendocrine Axis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We will conduct a prospective, controlled clinical trial of ovarian and menstrual cyclicity in TGN initiating TRT (Fig. 8). Enrollment will include 20 TGN and 20 cisgender female (CF) control subjects who report female gender identity congruent with female sex assignment at birth. All subjects will be age >18 y, with female sex assignment at birth, regular menstrual cycles, and body mass index 18-35 kg/m2. Subjects with history of prior T use, cancer, chemotherapy, or radiation of the brain, abdomen, or pelvis, current use of hormonal medications (including, but not limited to, metformin, insulin, progestins, or estrogenic medications), current endocrinopathy (including, but not limited to, PCOS, androgen secreting tumor, diabetes, or pituitary, thyroid, or adrenal disease), and renal, hepatic, cardiac, or hematologic disease will be excluded. TGN subjects will undergo baseline endocrine and menstrual cycle evaluation, followed by intramuscular (i.m.) administration of testosterone cypionate (TC) 50 mg (standard dose) every 7 d for 32 wks (Fig. 8). After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are independent of E2 signaling. TGN will collect first morning-voided urine daily at home for assessment of hormone levels during one complete menstrual cycle before TRT begins and continuing during TRT. Untreated CF controls will collect urine daily during one menstrual cycle. Urinary concentrations of LH, FSH, estrone (E1) conjugates, and pregnanediol glucuronide (PdG) will be measured via ELISA. Studies of steroidogenesis during the menopausal transition have demonstrated accuracy of monitoring urinary hormone metabolite levels to reconstruct ovarian cyclicity and ovulatory patterns170-173; we can use this methodology to track progression of any declining HPG axis output over time. All subjects will complete a daily uterine bleeding log using REDCap® and undergo weekly measurement of serum FSH, LH, E2, and P4 (ELISA), and T (LC-MS/MS) for confirmation of hormone dynamics demonstrated by urine hormone metabolite studies. TGN will also undergo weekly transvaginal ultrasound (US) using a 4- to 9-MHz probe to obtain three-dimensional (3D) pelvic imaging following initiation of TRT for confirmation of corpus luteum (CL) formation and regression analysis of hormone secretion patterns, endometrial thickness, antral follicle count (AFC), and volume of the uterus and ovaries. Changes in follicle dynamics will be studied with 3D US determination of the mean diameter of each antral in 1-mm increments from 2 to 9 mm, as in our prior reports174,175.
The primary endpoint will be Evidence of Luteal Activity (ELA), as defined by a 3-fold increase in urinary PdG level over baseline170,176. Basal urinary PdG levels, normalized to urinary creatinine excretion, will be determined based upon the minimum daily PdG level detected per cycle or 4-wk interval, as previously described170,176. Secondary endpoints will include mean serum FSH and LH levels, peak urinary LH concentration, and cumulative LH surge count. Follicular phase function will be defined per cycle (or per 4-wk interval in amenorrheic subjects) by creatinine-adjusted urinary E1 AUC. Five-day moving averages of creatinine-adjusted urinary FSH and LH levels will be calculated, with LH surge defined as a 3 standard deviation increase in the 5-d moving LH average, as previously described170,176. The proportion of subjects demonstrating an LH surge will be compared during successive 4-wk intervals.
We have already demonstrated successful recruitment and retention of TGN and CF participants in longitudinal studies involving daily urine collection and serial pelvic US (e.g., our study in Fig. 2 and others)174,175. TGN subjects will be serially evaluated for adverse effects of TRT per The Endocrine Society recommendations63. Details regarding safety monitoring are in the Human Subjects Section. We calculate that 15 subjects/group will have >95% power to detect a 30% decrease in the proportion of subjects with ELA at baseline compared to the final 4-week TC study interval (wks 21-24). Although we anticipate a larger, more clinically meaningful decrease, we have utilized a conservative target to maximize the study's power. Although we have had no dropouts in our current TGN pilot study, we factored a 20% dropout rate into our enrollment target of 20 subjects per group to ensure achieving sufficient power.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Tracy N Harrison, MD
- Phone Number: 858-822-1481
- Email: tnharrison@health.ucsd.edu
Study Contact Backup
- Name: Eunice Tingzon
- Phone Number: 858-534-8930
- Email: etingzon@health.ucsd.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Self-identified transgender or non-binary person assigned female at birth
- No history of prior testosterone therapy
- Regular menstrual cycles
- Body mass index 18 - 35
- Hemoglobin greater than than 11 gm/dl at screening evaluation
- Presence of uterus and both ovaries at time of consent
- Able to provide informed consent
- No current endocrine disease- including, but not limited to, pituitary disease, adrenal disease, androgen secreting tumor, polycystic ovary syndrome, diabetes, or untreated thyroid disease.
- Absence of cancer and any renal, hepatic, or cardiac disease
- No current use of endocrine modulating medications (including, but not limited to, progestin therapy, estrogen containing medications, metformin, insulin)
- No history of radiation or surgery involving brain, abdomen, or pelvis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Provocative Hormonal Testing
TGN subjects will undergo baseline endocrine and menstrual cycle evaluation, followed by intramuscular (i.m.) administration of testosterone cypionate (TC) 50 mg (standard dose) every 7 d for 32 wks (Fig. 8).
After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are independent of E2 signaling.
|
Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone.
Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air.
It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.
The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-.
Its molecular formula is C27H40O3, and the molecular weight 412.61.
Other Names:
Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis).
It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile.
Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.
It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C.
Letrozole is available as 2.5 mg tablets for oral administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence of Luteal Activity
Time Frame: Baseline, 12 weeks, 24 weeks, and 32 weeks
|
The primary endpoint will be Evidence of Luteal Activity (ELA), as defined by a 3-fold increase in urinary pregnanediol glucuronide level over baseline.
|
Baseline, 12 weeks, 24 weeks, and 32 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Androgens
- Anabolic Agents
- Letrozole
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- 200395
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Testosterone Cyp 200Mg/Ml Inj (in Oil)
-
University of Colorado, DenverCompletedKlinefelter SyndromeUnited States
-
Virginia Commonwealth UniversityUniversity of RwandaWithdrawn
-
Meshalkin Research Institute of Pathology of CirculationCompletedCardiac SurgeryRussian Federation
-
University Medical Centre LjubljanaCompletedObesity | HypogonadismSlovenia
-
University of Kansas Medical CenterRecruitingHypertension | Blood PressureUnited States
-
ANRS, Emerging Infectious DiseasesNot yet recruiting
-
Fundacion para la Investigacion Biomedica del Hospital...University of Alcala; Hospital Universitario Ramon y Cajal; Instituto de Salud... and other collaboratorsRecruitingPolycystic Ovary Syndrome | Hyperandrogenism | Type 1 Diabetes | Hirsutism | Oligomenorrhea | Ovulation DisorderSpain
-
University of ManitobaRecruitingPain, Postoperative | Liver Neoplasms | HepatectomyCanada